Poxviral-based vaccine elicits immunologic responses in prostate cancer patients

OncoImmunology

Volumn 3, Issue 4, 2014, Pages

  Madan, Ravi A ^a   Heery, Christopher R ^a   Gulley, James L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antigen spreading; Cancer vaccine; Immune response; Prostate cancer; T cell responses

Indexed keywords

ANTIANDROGEN; DOCETAXEL; IPILIMUMAB; RILIMOGENE GALVACIREPVEC;

ANTIGEN SPECIFICITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; FLU LIKE SYNDROME; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; INJECTION SITE REACTION; METASTASIS; PROSTATE CANCER; REGULATORY T LYMPHOCYTE;

EID: 84902596915     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.28611     Document Type: Article

References (10)

1. Madan RA, Arlen PM, Mohebtash M, Hodge JW, Gulley JL. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs 2009; 18:1001-11; PMID:19548854; http://dx.doi.org/10.1517/13543780902997928
2. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviralbased PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28:1099-105; PMID:20100959; http://dx.doi.org/10.1200/JCO.2009.25.0597
3. Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, Jones JL, Poole DJ, Higgins JP, Hodge JW, et al. Immunologic and prognostic factors associated with overall survival employing a poxviralbased PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 2010; 59:663-74; PMID:19890632; http://dx.doi.org/10.1007/s00262-009-0782-8
4. Gulley JL, Madan RA, Tsang KY, Jocehms C, Marte JL, Farsaci B, Tucker JA, Hodge JW, Liewehr DJ, Steinberg SM, et al. Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer. Cancer Immunol Res 2014:133-41.
5. Gulley JL, Heery CR, Madan RA, Walter BA, Merino MJ, Dahut WL, Tsang KY, Schlom J, Pinto PA. Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer. Cancer Immunol Immunother 2013; 62:1521-31; PMID:23836412; http://dx.doi.org/10.1007/s00262-013-1448-0
6. Disis ML, Wallace DR, Gooley TA, Dang Y, Slota M, Lu H, Coveler AL, Childs JS, Higgins DM, Fintak PA, et al. Concurrent trastuzumab and HER2/ neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol 2009; 27:4685-92; PMID:19720923; http://dx.doi.org/10.1200/JCO.2008.20.6789
7. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Mendrzyk R, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012; 18:1254-61; PMID:22842478; http://dx.doi.org/10.1038/nm.2883
8. Flammiger A, Weisbach L, Huland H, Tennstedt P, Simon R, Minner S, Bokemeyer C, Sauter G, Schlomm T, Trepel M. High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer. Eur J Cancer 2013; 49:1273-9; PMID:23266046; http://dx.doi.org/10.1016/j.ejca.2012.11.035
9. Stein WD, Gulley JL, Schlom J, Madan RA, Dahut W, Fig. WD, Ning YM, Arlen PM, Price D, Bates SE, et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials:the growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res 2011; 17:907-17; PMID:21106727; http://dx.doi.org/10.1158/1078-0432.CCR-10-1762
10. Madan RA, Gulley JL, Fojo T, Dahut WL. Therapeutic cancer vaccines in prostate cancer:the paradox of improved survival without changes in time to progression. Oncologist 2010; 15:969-75; PMID:20798195; http://dx.doi.org/10.1634/theoncologist.2010-0129